Elexis

Exelixis is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. The company's flagship product, cabozantinib (marketed as CABOMETYX and COMETRIQ), is a multi-tyrosine kinase inhibitor approved for various indications including renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Exelixis is actively expanding its oncology portfolio through internal R&D and strategic collaborations, advancing a pipeline of small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies. With a strong focus on targeted therapies and immunotherapies, the company aims to improve outcomes for patients across a broad range of solid tumors.